Two-Step Genome Editing Enables Creation of Full-Length Humanized Mouse Models

Why It Matters

The technology dramatically shortens the path to human‑relevant animal models, accelerating target validation and drug safety assessment across the biotech pipeline.

Key Takeaways

• TECHNO replaces mouse loci with >200 kb human DNA efficiently.
• Uses CRISPR/Cas9 landing site plus BAC-mediated integration.
• Humanized c‑Kit shows correct splicing and organ expression.
• APOBEC3 panel recapitulates human gene cluster regulation.
• Enables disease modeling, e.g., CYBB mutation for CGD.

Pulse Analysis

The quest for truly human‑like mouse models has long been hampered by the inability to transplant large genomic segments that include both coding sequences and their native regulatory landscapes. Traditional knock‑in strategies often truncate introns or replace promoters, leading to incomplete phenotypic recapitulation. TECHNO addresses these gaps by first excising the native mouse locus with CRISPR/Cas9 ribonucleoproteins and inserting a compact landing pad. In a second step, a bacterial artificial chromosome bearing the entire human gene—complete with introns, UTRs and distal enhancers—is integrated via homology‑directed repair, enabling seamless incorporation of fragments over 200 kb.

Proof‑of‑concept experiments underscore the platform’s versatility. Humanizing the c‑Kit locus restored species‑specific alternative splicing and organ‑restricted expression, while preserving hematopoietic and reproductive functions. The APOBEC3 cluster, spanning seven genes, was introduced intact, yielding expression profiles that mirror human immune cells. A disease‑relevant CYBB allele carrying CGD‑associated mutations reproduced the expected oxidative burst defect, validating the system for precise pathogenic modeling. These results demonstrate that large‑scale human genomic architecture can be faithfully maintained in vivo, opening avenues for studying complex regulatory variants.

Beyond academic inquiry, TECHNO is poised to reshape drug discovery and precision medicine pipelines. Companies can now generate high‑fidelity disease models to screen candidates earlier, reducing attrition rates linked to species‑specific pharmacodynamics. The method’s reliance on standard CRISPR reagents and widely available BAC libraries facilitates rapid adoption across laboratories, while its scalability supports the creation of extensive humanized allele libraries for AI‑driven comparative genomics. As functional genomics moves toward systems‑level integration, TECHNO offers a robust foundation for linking genotype to phenotype in a mammalian context.